BIO is pleased to announce the winners of the 2016 BIO Investor Forum Buzz of BIO contest, which recognizes highly innovative companies in the biotech sector. Ten pioneering biotech companies were nominated in each of two categories—Early Stage Entrepreneurs and Late Stage Leaders; voting closed August 23.
Sequella, a private, clinical-stage pharmaceutical company, won in the Early Stage Entrepreneurs category. The company is focused on antibiotic-resistant bacterial diseases and improved treatments for serious infectious diseases. Sequella’s stated business model is to leverage its core competencies in chemistry, microbiology, molecular biology, infectious diseases, and anti-infective R&D to discover, develop, and commercialize promising new antibiotics with excellent market potential. Learn more about Sequella.
Garnering the most votes in the Late Stage Leaders category was Quanterix, a venture capital backed company and the exclusive licensee of a broad intellectual property portfolio initially developed at Tufts University by Dr. David Walt, scientific founder of Quanterix and Illumina (NASDAQ: ILMN). Quanterix has developed an ultra-sensitive diagnostic platform that measures individual proteins at concentrations 1000 times lower than the best immunoassays available today. Lear more about Quanterix.
Congratulations to both companies! Each will receive complimentary conference registration, a company presentation and promotion to industry leaders including a spotlight in BioCentury Extra.
The 15th Annual BIO Investor Forum will take place October 18-19 at the Westin St. Francis hotel in San Francisco and will focus on investment opportunities for early stage and established private companies as well as emerging public companies.
Advance media registration is now available for qualified reporters working full time for print, broadcast and web publications with valid press credentials.
Visit us to learn more about the BIO Investor Forum, including registration, programming, company presentations and partnering information.